Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Chinese Patent Office
Julphar
Chubb
Cantor Fitzgerald
Teva
UBS
Deloitte
Johnson and Johnson
Queensland Health
McKinsey

Generated: August 16, 2017

DrugPatentWatch Database Preview

HALFLYTELY Drug Profile

« Back to Dashboard

Which patents cover Halflytely, and when can generic versions of Halflytely launch?

Halflytely is a drug marketed by Braintree and is included in one NDA. There is one patent protecting this drug and two Paragraph IV challenges.

The generic ingredient in HALFLYTELY is bisacodyl; polyethylene glycol 3350; potassium chloride; sodium bicarbonate; sodium chloride. There are five drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the bisacodyl; polyethylene glycol 3350; potassium chloride; sodium bicarbonate; sodium chloride profile page.

Summary for Tradename: HALFLYTELY

Patents:1
Applicants:1
NDAs:1
Bulk Api Vendors: see list55
Clinical Trials: see list8
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:HALFLYTELY at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Braintree
HALFLYTELY
bisacodyl; polyethylene glycol 3350; potassium chloride; sodium bicarbonate; sodium chloride
FOR SOLUTION, TABLET, DELAYED RELEASE;ORAL021551-003Jul 16, 2010DISCNYesNo► Subscribe► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: HALFLYTELY

Drugname Dosage Strength RLD Submissiondate
polyethylene glycol 3350, sodium chloride, sodium bicarbonate, potassium chloride and bisacodylFor Oral Solution and Delayed-release Tablet210 g, 5.6 g, 0.74 g, 2.86 g and 5 mg (1 Tablet Regimen)Halflytely7/30/2010
polyethylene glycol 3350, sodium chloride, sodium bicarbonate, potassium chloride and bisacodylFor Oral Solution and Delayed-210 g, 5.6 g, 0.74 g, 2.86 g and 5 mgHalflytely 1/28/2008
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Medtronic
Harvard Business School
Accenture
Moodys
Covington
Fuji
Federal Trade Commission
Deloitte
Teva
Chubb

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot